Letter to the editor

Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker for the prevention of type 2 diabetes mellitus?

Ching-Chu Chen^{a,b}, An-Na Chiang^c, Min-Huang Hsieh^a

^aDivision of Endocrinology and Metabolism, Department of Medicine, China Medical University Hospital, Taichung, Taiwan; ^bSchool of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan; ^cInstitute of

Biochemistry and Molecular Biology, National Yang-Ming University, Taipei, Taiwan

Running title: ACEI or ARB for the prevention of type 2 DM

Corresponding author: Dr. Ching-Chu Chen

Address: No 2, Yuh-Der Road, Taichung 40447, Taiwan

TEL: 886-4-22062121 Ext. 3489. Fax: 886-4-22038883.

E-mail:chingchu@ms15.hinet.net

word count of text: 573 number of figure: 1

Dear Editor

Previous large-scale clinical studies showed that the incidence of the new onset of diabetes as a secondary endpoint was lower in patients treated with either angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) than those individuals treated with other kinds of anti-hypertensive drugs or placebo [1]. These promising observations especially HOPE trial (ramipril vs placebo, 30% reduction in the new onset of diabetes, p < 0.001 in the *post hoc* analysis) led to the initiation of ramipril to prevent the development of diabetes as a primary endpoint in subjects with impaired fasting glucose [2]. However, the ramipril trial failed to reduce the incidence of diabetes at the end of the study [2]. In contrast, a recent prospective, large-scale, double-blind, placebo controlled study reported that valsartan significantly lowers the incidence of new-onset of diabetes in subjects with impaired glucose tolerance[3]. Why ramipril can not reduce the incidence of diabetes as valsartan is currently unknown. Here, we report the different effect on the activation of PPARy between ACEI and ARB, which may offer part of the speculations for the selection between these two drugs to prevent the development of diabetes in patients with hypertension and impaired fasting glucose or impaired glucose tolerance. The detailed description of the methods for measurement of PPARy activation and glucose uptake was reported in our previous study [4]. In brief, for the measurement of PPARy

2

activation, HuH-7 cells were transiently transfected with 0.5 µg of PPREy reporter constructs and 0.1 μg of cytomegalovirus-β-galactosidase vector (pCMV-β-Gal). After transfection, HuH-7cells were incubated in the presence of solvent alone (served as control) or varying doses of ACEI or ARB for 24 hrs. A 2 µM rosiglitazone was used as a positive control. The luciferase activity of PPREy reporter plasmid-transfected cells divided by the β -galactosidase activity of pCMV- β -Gal-transfected cells represents the relative PPARy activation of each experiment. As shown in figure, losartan and irbesartan instead of ramipril and imidapril significantly elevated PPARy activation in various doses in HuH-7cells. We further used 2-deoxy-D-[³H] glucose to evaluate the glucose uptake effect of irbesartan. We found that comparing with the control group, irbesartan at concentrations of 8 μ M (546.1 \pm 70.7 dpm vs 476.9 \pm 257.9 dpm, p < 0.05) and 10 μ M (725.9 \pm 367.7 dpm vs 476.9 \pm 257.9 dpm, p < 0.05) significantly increased the level of glucose uptake in 3T3-L1 cells. In conclusion, ARB increased PPARy activation and stimulated glucose uptake. Lack of the effect on the PPARy activation in ACEI may explain part of the mechanisms of the negative result of the ramipril study.

Key words: Angiotensin converting enzyme inhibitor, angiotensin II receptor blocker, DM

Conflict of interest

Dr Ching-Chu Chen has received lecture fee from MSD, Sanofi Aventis, Novatis and has been reimbursed by Sanofi Aventis for attending international diabetes conference. These companies manufacture ARB for the treatment of hypertension.

4

Acknowledgement

This work was supported by a grant from China Medical University Hospital (DMR 95004).

References

1. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the rennin-angiotensin system. Drugs 2004;64:2537-65.

 The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-62.

3. The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010. DOI: 10.1056/NEJMoa1001121.

4. Chen CC, Hsiang CY, Chiang AN, Lo HY, Li CI. Peroxisome proliferator-activated receptor gamma transactivation-mediated potentiation of glucose uptake by

Bai-Hu-Tang. J Ethnopharmacol 2008;118:46-50.




Figure. Activation of PPRE γ reporter gene (pGL-*tk*-(-32/+51)-4PPRE γ) activity by angiotensin II receptor blocker (losartan and irbesartan) but not angiotensin converting enzyme inhibitor (ramipril and imidapril) in HuH-7 cells. The PPAR γ activation of ACEI and ARB was presented as the relative activity of the control group. *p < 0.05, **p < 0.01, ***p < 0.005.